An Obesity Paradox: Increased Body Mass Index Is Associated with Decreased Aortic Atherosclerosis

Current Hypertension Reports

Volumn 19, Issue 7, 2017, Pages

  Barth, Rolf F ^a   Maximilian Buja, L ^b   Cao, Lei ^a   Brodsky, Sergey V ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

Atherosclerosis; Hypertension; Morbid obesity; Obesity paradox

Indexed keywords

AORTIC ATHEROSCLEROSIS; BODY MASS; CARDIOVASCULAR RISK; DISEASE ASSOCIATION; ENDOTHELIUM CELL; GENETIC VARIATION; HUMAN; INFLAMMATION; INTESTINE FLORA; MORBID OBESITY; NONHUMAN; OBESITY; PATHOGENESIS; PROTEIN FUNCTION; REVIEW; RISK REDUCTION; SHEAR STRESS; AORTA; ATHEROSCLEROSIS; GENETIC EPIGENESIS; GENETICS; HEMODYNAMICS; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY;

ADIPOCYTOKINE; MICRORNA; MIRN155 MICRORNA, HUMAN;

ADIPOKINES; AORTA; ATHEROSCLEROSIS; BODY MASS INDEX; EPIGENESIS, GENETIC; HEMODYNAMICS; HUMANS; MICRORNAS; OBESITY, MORBID;

EID: 85020678202     PISSN: 15226417     EISSN: 15343111     Source Type: Journal    
DOI: 10.1007/s11906-017-0753-y     Document Type: Review

References (52)

1. Brodsky SV, Barth RF, Mo X, Yildiz V, Allenby P, Ivanov I, et al. An obesity paradox: an inverse correlation between body mass index and atherosclerosis of the aorta. Cardiovasc Pathol. 2016;25(6):515–20. doi:10.1016/j.carpath.2016.09.002.
2. Kortelainen ML. Myocardial infarction and coronary pathology in severely obese people examined at autopsy. Int J Obes Relat Metab Disord J Int Assoc Study Obes. 2002;26(1):73–9. doi:10.1038/sj.ijo.0801852.
3. Kortelainen M-L, Porvari K. Extreme obesity and associated cardiovascular disease verified at autopsy: time trends over 3 decades. Am J Forensic Med Pathol. 2011;32(4):372–7.
4. Flegal KM, Kit BK, Orpana H, Graubard BI. Association of all-cause mortality with overweight and obesity using standard body mass index categories: a systematic review and meta-analysis. JAMA. 2013;309(1):71–82. doi:10.1001/jama.2012.113905.
5. Molica F, Morel S, Kwak BR, Rohner-Jeanrenaud F, Steffens S. Adipokines at the crossroad between obesity and cardiovascular disease. Thromb Haemost. 2015;113(3):553–66. doi:10.1160/th14-06-0513.
6. Ruscica M, Baragetti A, Catapano AL, Norata GD. Translating the biology of adipokines in atherosclerosis and cardiovascular diseases: gaps and open questions. Nutr Metab Cardiovasc Dis. 2016; doi:10.1016/j.numecd.2016.12.005.
7. Liberale L, Bonaventura A, Vecchie A, Matteo C, Dallegri F, Montecucco F, et al. The role of adipocytokines in coronary atherosclerosis. Curr Atheroscler Rep. 2017;19(2):10. doi:10.1007/s11883-017-0644-3.
8. Schmidt DS, Salahudeen AK. Obesity-survival paradox-still a controversy? Semin Dial. 2007;20(6):486–92. doi:10.1111/j.1525-139X.2007.00349.x.
9. Lavie CJ, De Schutter A, Milani RV. Healthy obese versus unhealthy lean: the obesity paradox. Nat Rev Endocrinol. 2015;11(1):55–62. doi:10.1038/nrendo.2014.165.
10. Goyal A, Nimmakayala KR, Zonszein J. Is there a paradox in obesity? Cardiol Rev. 2014;22(4):163–70. doi:10.1097/CRD.0000000000000004.
11. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet. 2005;365(9468):1415–28. doi:10.1016/S0140-6736(05)66378-7.
12. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120(16):1640–5. doi:10.1161/CIRCULATIONAHA.109.192644.
13. Orchard TJ. Dyslipoproteinemia and diabetes. Endocrinol Metab Clin N Am. 1990;19(2):361–80.
14. Tran TT, Kahn CR. Transplantation of adipose tissue and stem cells: role in metabolism and disease. Nat Rev Endocrinol. 2010;6(4):195–213. doi:10.1038/nrendo.2010.20.
15. Xu L, Panel V, Ma X, Du C, Hugendubler L, Gavrilova O, et al. The winged helix transcription factor Foxa3 regulates adipocyte differentiation and depot-selective fat tissue expansion. Mol Cell Biol. 2013;33(17):3392–9. doi:10.1128/MCB.00244-13.
16. Phillips CM. Metabolically healthy obesity: definitions, determinants and clinical implications. Rev Endocr Metab Disord. 2013;14(3):219–27. doi:10.1007/s11154-013-9252-x.
17. Phillips CM. Metabolically healthy obesity: personalised and public health implications. Trends Endocrinol Metab. 2016;27(4):189–91. doi:10.1016/j.tem.2016.02.001.
18. Phillips CM. Metabolically healthy obesity across the life course: epidemiology, determinants, and implications. Ann N Y Acad Sci. 2017;1391(1):85–100. doi:10.1111/nyas.13230.
19. Lavie CJ, Sharma A, Alpert MA, De Schutter A, Lopez-Jimenez F, Milani RV, et al. Update on obesity and obesity paradox in heart failure. Prog Cardiovasc Dis. 2016;58(4):393–400. doi:10.1016/j.pcad.2015.12.003.
20. Lavie CJ, De Schutter A, Parto P, Jahangir E, Kokkinos P, Ortega FB, et al. Obesity and prevalence of cardiovascular diseases and prognosis-the obesity paradox updated. Prog Cardiovasc Dis. 2016;58(5):537–47. doi:10.1016/j.pcad.2016.01.008.
21. Wildman RP, Muntner P, Reynolds K, McGinn AP, Rajpathak S, Wylie-Rosett J, et al. The obese without cardiometabolic risk factor clustering and the normal weight with cardiometabolic risk factor clustering: prevalence and correlates of 2 phenotypes among the US population (NHANES 1999-2004). Arch Intern Med. 2008;168(15):1617–24. doi:10.1001/archinte.168.15.1617.
22. Lee SH, Ha HS, Park YJ, Lee JH, Yim HW, Yoon KH, et al. Identifying metabolically obese but normal-weight (MONW) individuals in a nondiabetic Korean population: the Chungju metabolic disease cohort (CMC) study. Clin Endocrinol. 2011;75(4):475–81. doi:10.1111/j.1365-2265.2011.04085.x.
23. Meigs JB, Wilson PW, Fox CS, Vasan RS, Nathan DM, Sullivan LM, et al. Body mass index, metabolic syndrome, and risk of type 2 diabetes or cardiovascular disease. J Clin Endocrinol Metab. 2006;91(8):2906–12. doi:10.1210/jc.2006-0594.
24. Dhurandhar NV. Insulin sparing action of adenovirus 36 and its E4orf1 protein. J Diabetes Complicat. 2013;27(2):191–9. doi:10.1016/j.jdiacomp.2012.09.006.
25. McMurphy TB, Huang W, Xiao R, Liu X, Dhurandhar NV, Cao L. Hepatic expression of adenovirus 36 E4ORF1 improves glycemic control and promotes glucose metabolism through AKT activation. Diabetes. 2017;66(2):358–71. doi:10.2337/db16-0876.
26. Hu E, Liang P, Spiegelman BM. AdipoQ is a novel adipose-specific gene dysregulated in obesity. J Biol Chem. 1996;271(18):10697–703.
27. Yamauchi T, Kamon J, Waki H, Imai Y, Shimozawa N, Hioki K, et al. Globular adiponectin protected ob/ob mice from diabetes and ApoE-deficient mice from atherosclerosis. J Biol Chem. 2003;278(4):2461–8. doi:10.1074/jbc.M209033200.
28. van Stijn CM, Kim J, Barish GD, Tietge UJ, Tangirala RK. Adiponectin expression protects against angiotensin II-mediated inflammation and accelerated atherosclerosis. PLoS One. 2014;9(1):e86404.
29. Ouchi N, Kihara S, Arita Y, Nishida M, Matsuyama A, Okamoto Y, et al. Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation. 2001;103(8):1057–63.
30. Mattu HS, Randeva HS. Role of adipokines in cardiovascular disease. J Endocrinol. 2013;216(1):T17–36. doi:10.1530/JOE-12-0232.
31. Kim JY, van de Wall E, Laplante M, Azzara A, Trujillo ME, Hofmann SM, et al. Obesity-associated improvements in metabolic profile through expansion of adipose tissue. J Clin Invest. 2007;117(9):2621–37. doi:10.1172/JCI31021.
32. Mo C, Yang M, Han X, Li J, Gao G, Tai H, et al. Fat mass and obesity-associated protein attenuates lipid accumulation in macrophage foam cells and alleviates atherosclerosis in apolipoprotein E-deficient mice. J Hypertens. 2017;35(4):810–21. doi:10.1097/hjh.0000000000001255.
33. Lee Y, Naseem RH, Duplomb L, Park BH, Garry DJ, Richardson JA, et al. Hyperleptinemia prevents lipotoxic cardiomyopathy in acyl CoA synthase transgenic mice. Proc Natl Acad Sci U S A. 2004;101(37):13624–9. doi:10.1073/pnas.0405499101.
34. Hoffmann A, Ebert T, Kloting N, Dokas J, Jeromin F, Jessnitzer B, et al. Leptin dose-dependently decreases atherosclerosis by attenuation of hypercholesterolemia and induction of adiponectin. Biochim Biophys Acta. 2016;1862(1):113–20. doi:10.1016/j.bbadis.2015.10.022.
35. Beltowski J. Leptin and atherosclerosis. Atherosclerosis. 2006;189(1):47–60. doi:10.1016/j.atherosclerosis.2006.03.003.
36. Virtue A, Johnson C, Lopez-Pastraña J, Shao Y, Fu H, Li X, et al. MicroRNA-155 deficiency leads to decreased atherosclerosis, increased white adipose tissue obesity, and non-alcoholic fatty liver disease a novel mouse model of obesity paradox. J Biol Chem. 2017;292(4):1267–87.
37. Berezina A, Belyaeva O, Berkovich O, Baranova E, Karonova T, Bazhenova E, et al. Prevalence, risk factors, and genetic traits in metabolically healthy and unhealthy obese individuals. Biomed Res Int. 2015;2015:548734. doi:10.1155/2015/548734.
38. Davis AE, Lewandowski AJ, Holloway CJ, Ntusi NA, Banerjee R, Nethononda R, et al. Observational study of regional aortic size referenced to body size: production of a cardiovascular magnetic resonance nomogram. J Cardiovasc Magn Reson. 2014;16:9. doi:10.1186/1532-429x-16-9.
39. Cowan GS Jr, Defibaugh N, White T, Hiler ML, Somes G. Aorta and iliac arterial sizes in pre-operative morbidly obese patients: a preliminary report. Obes Surg. 1991;1(2):155–9.
40. Fry DL. Acute vascular endothelial changes associated with increased blood velocity gradients. Circ Res. 1968;22(2):165–97.
41. Wellnhofer E, Bocksch W, Hiemann N, Dandel M, Klimek W, Hetzer R, et al. Shear stress and vascular remodeling: study of cardiac allograft coronary artery disease as a model of diffuse atherosclerosis. J Heart Lung Transplant. 2002;21(4):405–16.
42. Lee BK, Kwon HM, Hong BK, Park BE, Suh SH, Cho MT, et al. Hemodynamic effects on atherosclerosis-prone coronary artery: wall shear stress/rate distribution and impedance phase angle in coronary and aortic circulation. Yonsei Med J. 2001;42(4):375–83. doi:10.3349/ymj.2001.42.4.375.
43. Friedman MH. Some atherosclerosis may be a consequence of the normal adaptive vascular response to shear. Atherosclerosis. 1990;82(3):193–6.
44. Friedman MH, Deters OJ, Bargeron CB, Hutchins GM, Mark FF. Shear-dependent thickening of the human arterial intima. Atherosclerosis. 1986;60(2):161–71.
45. Heo KS, Fujiwara K, Abe J. Disturbed-flow-mediated vascular reactive oxygen species induce endothelial dysfunction. Circ J. 2011;75(12):2722–30.
46. Garin G, Abe J, Mohan A, Lu W, Yan C, Newby AC, et al. Flow antagonizes TNF-alpha signaling in endothelial cells by inhibiting caspase-dependent PKC zeta processing. Circ Res. 2007;101(1):97–105. doi:10.1161/circresaha.107.148270.
47. Reinhart-King CA, Fujiwara K, Berk BC. Physiologic stress-mediated signaling in the endothelium. Methods Enzymol. 2008;443:25–44. doi:10.1016/s0076-6879(08)02002-8.
48. Jonsson AL, Bäckhed F. Role of gut microbiota in atherosclerosis. Nat Rev Cardiol. 2017;14(2):79–87. doi:10.1038/nrcardio.2016.183.
49. Benagiano M, Munari F, Ciervo A, Amedei A, Paccani SR, Mancini F, et al. Chlamydophila pneumoniae phospholipase D (CpPLD) drives Th17 inflammation in human atherosclerosis. Proc Natl Acad Sci U S A. 2012;109(4):1222–7. doi:10.1073/pnas.1111833109.
50. Galkina E, Ley K. Immune and inflammatory mechanisms of atherosclerosis. Annu Rev Immunol. 2009;27:165–97. doi:10.1146/annurev.immunol.021908.132620.
51. Ravnskov U, McCully KS. Infections may be causal in the pathogenesis of atherosclerosis. Am J Med Sci. 2012;344(5):391–4. doi:10.1097/MAJ.0b013e31824ba6e0.
52. Zink A, Wann LS, Thompson RC, Keller A, Maixner F, Allam AH, et al. Genomic correlates of atherosclerosis in ancient humans. Glob Heart. 2014;9(2):203–9. doi:10.1016/j.gheart.2014.03.2453.